Jeff Jones
Stock Analyst at Oppenheimer
(0.86)
# 3,773
Out of 4,876 analysts
93
Total ratings
23.81%
Success rate
-18.34%
Average return
Main Sectors:
Stocks Rated by Jeff Jones
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVBP ArriVent BioPharma | Maintains: Outperform | $39 → $44 | $22.85 | +92.56% | 3 | Jun 24, 2025 | |
| YMAB Y-mAbs Therapeutics | Maintains: Outperform | $20 → $15 | $4.69 | +219.83% | 3 | May 29, 2025 | |
| CMMB Chemomab Therapeutics | Maintains: Outperform | $11 → $10 | $1.17 | +753.75% | 8 | May 16, 2025 | |
| ALMS Alumis | Maintains: Outperform | $26 → $25 | $3.12 | +701.28% | 2 | May 15, 2025 | |
| ZURA Zura Bio | Maintains: Outperform | $19 → $17 | $1.13 | +1,411.11% | 4 | May 9, 2025 | |
| CRVS Corvus Pharmaceuticals | Reiterates: Outperform | $15 → $17 | $3.94 | +331.47% | 5 | May 9, 2025 | |
| IMCR Immunocore Holdings | Maintains: Outperform | $85 → $86 | $31.45 | +173.45% | 2 | May 8, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Outperform | $60 → $56 | $7.90 | +608.86% | 9 | May 7, 2025 | |
| EVH Evolent Health | Maintains: Outperform | $28 → $18 | $11.00 | +63.64% | 4 | Jan 24, 2025 | |
| CLRB Cellectar Biosciences | Downgrades: Perform | n/a | $8.04 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $16 | $3.61 | +343.21% | 7 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 → $9 | $2.46 | +265.85% | 10 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $56 | $44.07 | +27.07% | 4 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $45 | $1.31 | +3,348.28% | 6 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $9.37 | - | 4 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.09 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,920 | $0.34 | +564,605.88% | 3 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.34 | - | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $1.07 | +1,301.87% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $75 | $0.32 | +23,425.72% | 2 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,600 → $1,100 | $2.57 | +42,701.56% | 2 | Nov 17, 2022 |
ArriVent BioPharma
Jun 24, 2025
Maintains: Outperform
Price Target: $39 → $44
Current: $22.85
Upside: +92.56%
Y-mAbs Therapeutics
May 29, 2025
Maintains: Outperform
Price Target: $20 → $15
Current: $4.69
Upside: +219.83%
Chemomab Therapeutics
May 16, 2025
Maintains: Outperform
Price Target: $11 → $10
Current: $1.17
Upside: +753.75%
Alumis
May 15, 2025
Maintains: Outperform
Price Target: $26 → $25
Current: $3.12
Upside: +701.28%
Zura Bio
May 9, 2025
Maintains: Outperform
Price Target: $19 → $17
Current: $1.13
Upside: +1,411.11%
Corvus Pharmaceuticals
May 9, 2025
Reiterates: Outperform
Price Target: $15 → $17
Current: $3.94
Upside: +331.47%
Immunocore Holdings
May 8, 2025
Maintains: Outperform
Price Target: $85 → $86
Current: $31.45
Upside: +173.45%
Corbus Pharmaceuticals Holdings
May 7, 2025
Maintains: Outperform
Price Target: $60 → $56
Current: $7.90
Upside: +608.86%
Evolent Health
Jan 24, 2025
Maintains: Outperform
Price Target: $28 → $18
Current: $11.00
Upside: +63.64%
Cellectar Biosciences
Dec 11, 2024
Downgrades: Perform
Price Target: n/a
Current: $8.04
Upside: -
Nov 22, 2024
Maintains: Outperform
Price Target: $22 → $16
Current: $3.61
Upside: +343.21%
Nov 8, 2024
Reiterates: Outperform
Price Target: $10 → $9
Current: $2.46
Upside: +265.85%
Sep 27, 2024
Maintains: Outperform
Price Target: $52 → $56
Current: $44.07
Upside: +27.07%
Aug 8, 2024
Maintains: Outperform
Price Target: $48 → $45
Current: $1.31
Upside: +3,348.28%
Jun 7, 2024
Downgrades: Perform
Price Target: n/a
Current: $9.37
Upside: -
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.09
Upside: -
May 25, 2023
Maintains: Outperform
Price Target: $1,920
Current: $0.34
Upside: +564,605.88%
May 23, 2023
Downgrades: Perform
Price Target: n/a
Current: $3.34
Upside: -
May 11, 2023
Reiterates: Outperform
Price Target: $15
Current: $1.07
Upside: +1,301.87%
Mar 24, 2023
Reiterates: Outperform
Price Target: $75
Current: $0.32
Upside: +23,425.72%
Nov 17, 2022
Maintains: Outperform
Price Target: $1,600 → $1,100
Current: $2.57
Upside: +42,701.56%